CN105209011B - 液体的局部药用的纳米乳液制剂 - Google Patents

液体的局部药用的纳米乳液制剂 Download PDF

Info

Publication number
CN105209011B
CN105209011B CN201380074085.1A CN201380074085A CN105209011B CN 105209011 B CN105209011 B CN 105209011B CN 201380074085 A CN201380074085 A CN 201380074085A CN 105209011 B CN105209011 B CN 105209011B
Authority
CN
China
Prior art keywords
composition
transdermal
active ingredient
final concentration
transdermal composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380074085.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN105209011A (zh
Inventor
F·L·乔丹
C·乔丹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JRX Biotechnology Inc
Original Assignee
JRX Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JRX Biotechnology Inc filed Critical JRX Biotechnology Inc
Priority to CN201910440636.0A priority Critical patent/CN110201180A/zh
Publication of CN105209011A publication Critical patent/CN105209011A/zh
Application granted granted Critical
Publication of CN105209011B publication Critical patent/CN105209011B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380074085.1A 2012-12-31 2013-12-27 液体的局部药用的纳米乳液制剂 Active CN105209011B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910440636.0A CN110201180A (zh) 2012-12-31 2013-12-27 液体的局部药用的纳米乳液制剂

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261748036P 2012-12-31 2012-12-31
US61/748,036 2012-12-31
US201361758726P 2013-01-30 2013-01-30
US61/758,726 2013-01-30
PCT/US2013/077985 WO2014106048A2 (en) 2012-12-31 2013-12-27 Liquid topical pharmaceutical nano-emulsion formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910440636.0A Division CN110201180A (zh) 2012-12-31 2013-12-27 液体的局部药用的纳米乳液制剂

Publications (2)

Publication Number Publication Date
CN105209011A CN105209011A (zh) 2015-12-30
CN105209011B true CN105209011B (zh) 2019-06-25

Family

ID=51022202

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380074085.1A Active CN105209011B (zh) 2012-12-31 2013-12-27 液体的局部药用的纳米乳液制剂
CN201910440636.0A Pending CN110201180A (zh) 2012-12-31 2013-12-27 液体的局部药用的纳米乳液制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910440636.0A Pending CN110201180A (zh) 2012-12-31 2013-12-27 液体的局部药用的纳米乳液制剂

Country Status (10)

Country Link
US (2) US20150374835A1 (https=)
EP (1) EP2938324B1 (https=)
JP (1) JP6403686B2 (https=)
KR (1) KR20150102058A (https=)
CN (2) CN105209011B (https=)
BR (1) BR112015015788A2 (https=)
EA (1) EA201591015A1 (https=)
ES (1) ES2969933T3 (https=)
SG (1) SG11201505076UA (https=)
WO (1) WO2014106048A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596117B1 (en) 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds
US10561627B2 (en) 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
US11007161B1 (en) 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films
US11260018B2 (en) 2015-09-17 2022-03-01 Jrx Biotechnology, Inc. Approaches for improving skin hydration and moisturization
DK3518672T3 (da) 2016-09-29 2026-02-09 Jrx Biotechnology Inc Fremgangsmåder til ændring af plantevækst og reducering af planters vandforbrug
PL3558269T3 (pl) 2016-12-21 2024-11-18 Dukebox Spółka Z Ograniczoną Odpowiedzialnością Sposób wytwarzania emulsji woda w oleju nanocząsteczek paracetamolu
US11634368B2 (en) * 2018-03-28 2023-04-25 Jrx Biotechnology, Inc. Agricultural compositions
KR102117651B1 (ko) 2018-04-27 2020-06-02 대구가톨릭대학교산학협력단 항산화, 주름개선 또는 염증개선용 한방 조성물 및 이를 포함하는 화장료 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1874740A (zh) * 2003-10-10 2006-12-06 奥来克西公司 经皮高分子量和低分子量化合物
WO2009019604A2 (en) * 2007-08-09 2009-02-12 Ems S/A Delivery systems for solubilising water-insoluble pharmaceutical active ingredients

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374766A (en) 1982-06-01 1983-02-22 Charles Of The Ritz Group Ltd. Combined allantoin-hydrolyzed animal protein product and method
US4973473A (en) 1989-06-23 1990-11-27 Revlon, Inc. Skin care preparation
IT1232318B (it) 1989-09-07 1992-01-28 Crinos Industria Farmaco Composizioni ad uso topico contenenti acidi nucleici depolimerizzati per la cosmesi della pelle e del corpo.
US5153174A (en) 1989-10-30 1992-10-06 Union Carbide Chemicals & Plastics Inc. Polymer mixtures useful in skin care
JP3172177B2 (ja) 1990-11-14 2001-06-04 イミュー プロダクツ ウェスターン オーストレイリア ピーティーワイ． リミテッド エミュー油から誘導した抗炎性混合物
US5297562A (en) 1991-04-01 1994-03-29 President And Fellows Of Harvard College Method for detecting and treating Alzheimer's disease
IL101387A (en) 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
US5614212A (en) 1992-04-08 1997-03-25 International Medical Associates, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5318960A (en) 1992-06-03 1994-06-07 Frank Toppo System for transdermal delivery of pain relieving substances
KR940021073A (ko) 1993-03-02 1994-10-17 미야베 요시가즈 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i
US6113921A (en) * 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
US6103246A (en) 1993-06-03 2000-08-15 Tisdale; Carrie J. Creams and lotions containing emu oil
US5840746A (en) 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US5472713A (en) 1994-11-23 1995-12-05 Elf Resources, Inc. Therapeutic uses of emu oil
US5716625A (en) 1994-12-21 1998-02-10 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5744128A (en) 1995-05-03 1998-04-28 Holick; Michael F. Use of emu oil for stimulating skin and hair growth
AUPN531195A0 (en) 1995-09-11 1995-10-05 J.W. Broadbent Nominees Pty. Ltd. Lipid extract having anti-inflamatory activity
US5939082A (en) 1995-11-06 1999-08-17 The Procter & Gamble Company Methods of regulating skin appearance with vitamin B3 compound
IT1289845B1 (it) 1996-01-10 1998-10-16 Guido Paduano Formula per il trattamento della cute e suoi impieghi
US5891857A (en) 1996-02-20 1999-04-06 Vanderbilt University Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
JP2000506062A (ja) 1996-03-01 2000-05-23 株式会社 荏原製作所 電子ビーム照射による脱硫方法及び装置
US5891651A (en) 1996-03-29 1999-04-06 Mayo Foundation For Medical Education And Research Methods of recovering colorectal epithelial cells or fragments thereof from stool
US5861268A (en) 1996-05-23 1999-01-19 Biomide Investment Limited Partnership Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase
US5708038A (en) 1996-06-13 1998-01-13 Univera Pharmaceuticals, Inc. Method of using aloe vera as a biological vehicle
US5698227A (en) 1996-07-23 1997-12-16 Rivlin; Daniel Compositions comprising lidocaine and emu oil and methods of use thereof
JP2001516340A (ja) 1996-12-31 2001-09-25 アメリカン、メディカル、リサーチ、インコーポレーテッド 抗菌性、抗ウイルス性、防腐性、および治癒性が持続する皮膚用製品
AU6046198A (en) 1997-01-31 1998-08-25 Kenneth Hoyt Use of oil from emu or rhea birds as trans-membrane carriers for delivery of drugs, peptides and vaccines
US5945446A (en) 1997-02-10 1999-08-31 Laubc Biochemicals, Corporation Process for preparing synthetic soil-extract materials and medicaments based thereon
ATE265847T1 (de) 1997-07-29 2004-05-15 Upjohn Co Selbstemulgierbare formulierung enthaltend lipophile verbindungen
US5885597A (en) 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain
ID25908A (id) 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
CA2331640A1 (en) 1998-05-07 1999-11-11 Elan Corporation Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
AR018376A1 (es) * 1998-05-26 2001-11-14 Novartis Ag Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
AU4972599A (en) 1998-07-07 2000-01-24 Transdermal Technologies, Inc. Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof
US7220427B2 (en) 1998-07-08 2007-05-22 Oryxe Mixture for transdermal delivery of low and high molecular weight compounds
AU5093199A (en) 1998-07-08 2000-02-01 Oryxe Transdermal delivery system
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
FR2787703B1 (fr) * 1998-12-29 2001-01-26 Oreal Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
US20060121103A1 (en) 2000-05-11 2006-06-08 Kenneth Kirby Transdermal delivery system
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20080154210A1 (en) * 2004-05-28 2008-06-26 Oryxe Mixture for Transdermal Delivery of Low and High Molecular Weight Compounds
WO2006041538A2 (en) 2004-05-28 2006-04-20 Oryxe A mixture for transdermal delivery of low and high molecular weight compounds
US20050271752A1 (en) * 2004-06-04 2005-12-08 Roth Ivar E Antifungal products and method of use
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
WO2006113668A1 (en) * 2005-04-15 2006-10-26 University Of South Florida A method of transdermal drug delivery using hyaluronic acid nanoparticles
US20070264346A1 (en) 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
EP2001439A2 (en) 2006-03-07 2008-12-17 Novavax, Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
WO2009021526A1 (de) * 2007-07-25 2009-02-19 S & V Technologies Ag Hyaluronsäuredispersion, herstellung und anwendung
DE102008034944B4 (de) * 2008-07-26 2017-03-16 Arivine Pharma Ag Mikroemulsion
CN102389401B (zh) 2011-11-22 2013-05-22 陆荣政 一种右旋布洛芬颗粒及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1874740A (zh) * 2003-10-10 2006-12-06 奥来克西公司 经皮高分子量和低分子量化合物
WO2009019604A2 (en) * 2007-08-09 2009-02-12 Ems S/A Delivery systems for solubilising water-insoluble pharmaceutical active ingredients

Also Published As

Publication number Publication date
US12285487B2 (en) 2025-04-29
US20150374835A1 (en) 2015-12-31
WO2014106048A2 (en) 2014-07-03
HK1218723A1 (zh) 2017-03-10
BR112015015788A2 (pt) 2017-07-11
SG11201505076UA (en) 2015-07-30
KR20150102058A (ko) 2015-09-04
EP2938324B1 (en) 2023-11-08
US20200009257A1 (en) 2020-01-09
EP2938324A2 (en) 2015-11-04
WO2014106048A3 (en) 2014-08-21
JP2016508141A (ja) 2016-03-17
ES2969933T3 (es) 2024-05-23
EA201591015A1 (ru) 2016-05-31
CN105209011A (zh) 2015-12-30
HK1216719A1 (en) 2016-12-02
JP6403686B2 (ja) 2018-10-10
EP2938324A4 (en) 2016-09-28
CN110201180A (zh) 2019-09-06

Similar Documents

Publication Publication Date Title
CN105209011B (zh) 液体的局部药用的纳米乳液制剂
JP5709826B2 (ja) 治療用組成物
US20130224268A1 (en) Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same
US20140079785A1 (en) Composition comprising lipid nanoparticles and a corticosteroid or vitamin d derivative
JP2020521810A (ja) ビファシックス（ｂｉｐｈａｓｉｘ）・カンナビノイド送達
Indora et al. Design, development and evaluation of ethosomal gel of fluconazole for topical fungal infection
JPH09510980A (ja) 生物付着性物質としての脂肪酸エステルの使用
Campaña-Seoane et al. Bioadhesive emulsions for control release of progesterone resistant to vaginal fluids clearance
Bora et al. Recent advances in semisolid dosage form
Radicioni et al. Comparative bioavailability study of a new vitamin D3 orodispersible film versus a marketed oral solution in healthy volunteers
RU2555339C2 (ru) Нанокристаллы кальципотриола моногидрита
Sharma et al. Formulation development and pharmacokinetic investigation of self-assembled hybrid niosomes for oral delivery of 17-Hydroxyprogesterone caproate
TWI393576B (zh) 供雄激素透黏膜投予用的呈膜形式之黏膜黏著性藥學組成物
Musko et al. The use of compounded dispersing media for extemporaneous pediatric syrups with candesartan cilexetil and valsartan
CN104023717B (zh) 包括脂质微胶囊递送媒剂的局部调配物和其用途
HK1218723B (zh) 液体的局部药用的纳米乳液制剂
HK40013799A (en) Liquid topical pharmaceutical nano-emulsion formulations
HK1216719B (en) Liquid topical pharmaceutical nano-emulsion formulations
Söpper Development of mucoadhesive carrier systems for flavoring agents and cannabidiol
Ulayya et al. Nanoemulgel Optimization of Achatina fulica Mucus: A D-Optimal Mixture Design Approach for Enhanced Formulation and Penetration Evaluation In Vitro
Kushwaha et al. Nanostructured Lipid Carrier (NLCs)-Based Topical Gel of Tofacitinib for IMQ-Induced Psoriasis: Design In-Vitro and In-Vivo Assessment
CN101522198B (zh) 用于治疗牛皮癣的药用制剂
BR102021004247A2 (pt) Sistema carreador para liberação controlada de ativos lipofílicos no meio subcutâneo e uso de sistema carreador para liberação controlada de ativos lipofílicos no meio subcutâneo
Dartora et al. Quality evaluation of minoxidil topical solutions obtained from magistral pharmacies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant